The root cause of tumors can be attributed to the continuous growth of tumor cells. The most important difference between tumor cells and normal cells is that mutant gene (driver gene) that drives tumorigenesis is produced. Therefore, tumors are essentially genetic diseases. Next generation sequencing (NGS) is a high-throughput sequencing method to understand tumors from the gene level, detect and quantify the genetic components that drive tumorigenesis, and then according to the results of testing, targeted drugs and immune drugs can be recommended to patients, prolong the survival time of patients, improve the quality of life, and cure tumors as much as possible.
At present, with more and more tumor targeted drugs and immune drugs approved for marketing and even included in medical insurance, genetic testing has gradually become a routine means of cancer treatment. Based on the diversity of these targeted drugs, clinical testing needs have evolved from a single gene to a multi-gene parallel test—NGS testing can detect dozens or even hundreds of genes at once, screening for the possibility of all medications, and make up for the deficiency of traditional methods in detecting immune markers like TMB and MSI.